[Therapeutic strategies for hepatitis C].
Tsubota
Akihito
A
Institute of Clinical Medicine and Research, Jikei University School of Medicine.
Kumada
Hiromitsu
H
D000998:Antiviral Agents / Q000008:administration & dosage*; D003545:Cysteine / Q000627:therapeutic use; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D005838:Genotype; D005998:Glycine / Q000627:therapeutic use; D016174:Hepacivirus / Q000235:genetics; D006526:Hepatitis C / Q000628:therapy*; D006801:Humans; D007370:Interferon Type I / Q000008:administration & dosage; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage; D007372:Interferons / Q000008:administration & dosage* / Q000009:adverse effects; D009828:Oleanolic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010597:Pharmacogenetics; D018962:Phlebotomy; D011092:Polyethylene Glycols / Q000008:administration & dosage; D011994:Recombinant Proteins; D012254:Ribavirin / Q000008:administration & dosage; D014580:Ursodeoxycholic Acid / Q000627:therapeutic use
D000998:Antiviral Agents; D004338:Drug Combinations; D007370:Interferon Type I; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C050739:interferon alfacon-1; D009828:Oleanolic Acid; C009781:neominophagen C; D014580:Ursodeoxycholic Acid; D007372:Interferons; C417083:peginterferon alfa-2b; D003545:Cysteine; C100416:peginterferon alfa-2a; D005998:Glycine